Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes?

Authors
Category Primary study
JournalCancer cell
Year 2019
It has been widely assumed that PD-1 blockade works by reinvigorating ("rebooting") pre-existing exhausted tumor-infiltrating ilymphocytes (TILs). A recent study challenges this paradigm, demonstrating that the majority of tumor-specific TILs after anti-PD-1 treatment have TCRs not identified in the tumor pre-therapy, suggesting they are newly recruited post-therapy.
Epistemonikos ID: 6a668e0e2bcc00b6a0e3d7b6099ce6b5c9f6652d
First added on: Nov 07, 2024